tbuckley/cabot-search huggingface dataset:
Survival of lung cancer patients with bone metastases
Authors: Evica Budisin, Nikola Budisin, Marijela Potic, Olga Budisin, Dejan Vuckovic
Journal: European Respiratory Journal (2011)

The presence of metastatic deseases in lung cancer patients is common in everyday clinical practice.

The aim of this study is to establish frequences of bone metastases in our patients (pts). and their association with other metastases (as brain, liver etc.) and to investigate their survival and treatment effects.

Methods: The data were collected from the Hospital Registry. The investigation was carried out in non operated patients. It included 1197 newly discovered lung cancer patients., 71 (5,93%) patients had bone metastases. In the moment of the dates analysis, 62 (87,3%) were dead, and the mean survival was 2.5 month (survival range 0.1-13month). Solitary bone matastases have 25 (35,2%) patients., and multiple bone metastases have 46 (64,8%) patients, while bone and other metastases were found in 37 (52,1%) patients. Only 14 (19,7%) patients were treated with bifosfonats therapy, and their mean survival was 2 months.

Conclusion: Lung cancer patients with bone metastases, usually associated with other metastases, achieved a wary poor surviival. Neither the paliativ irradiation of solitary metastases nor bifosfonats therapy improved the survival of lung cancer patients.
A prospective, randomized, open-label, phase III clinical trial of NovoTTF-100A versus best standard of care chemotherapy in patients with recurrent glioblastoma.
Authors: R. Stupp, A. Kanner, H. Engelhard, V. Heidecke, S. Taillibert, F. S. Lieberman, V. Dbalý, E. D. Kirson, Y. Palti, P. H. Gutin
Journal: Journal of Clinical Oncology (2010)

LBA2007 Background: The NovoTTF is a portable, medical device delivering low intensity, intermediate frequency, alternating electric fields by means of noninvasive, disposable scalp electrodes. These tumor treatment fields (TTF) physically interfere with cell division and assembly of organelles. Methods: Adult pts (KPS≥70%) with recurrent GBM were randomized (stratified by surgery for recurrence and center) to either NovoTTF administered continuously (20-24h/day, 7 days/week) or the best standard chemotherapy (BSC) at each physicians’ discretion. Number of prior therapies was not limited. Primary endpoint was overall survival (OS). The study was powered (80%) to detect a 60% increase in OS with a two tailed a of 0.05. Results: 237 pts were randomized (28 centers in the United States and Europe) to either TTF alone (120 pts) or BSC (117 pts). Patient characteristics were balanced, median age was 54 years (range 23-80), median KPS 80% (50-100). All had prior TMZ/RT, and the majority at least one prior therapy for recurrence. One-quarter had surgery for recurrence. Mean treatment duration was 4.4 mo (0-40) vs. 2.3 mo (0-15), median OS was 6.6 vs. 6.0 months for TTF and BSC, respectively (p=0.23, hazard ratio 0.84 [95% CI 0.63-1.12]), the 1-year survival rate 23.6% versus 20.8% (ns). PFS6 was 17.6% in both groups. Time to treatment failure favored the TTF group (HR 0.76 [0.57-1.02], p=0.07). Objective responses were more common in the TTF arm (12%) versus the BSC (6%). Related adverse events were mild-to-moderate skin rash beneath the electrodes in 17% of TTF treated pts. Hematological and other toxicities were observed at a significantly higher incidence in the BSC arm depending on the type of chemotherapy, no treatment-related deaths occurred. Treatment compliance with TTF was excellent with a median duration 20 hours/day. Conclusions: This is the first phase III, controlled clinical trial testing TTF, an entirely novel treatment modality. TTF had minimal toxicity, long-term treatment proved feasible. TTF as a single modality showed a higher response rate and longer time to treatment failure compared to best available chemotherapy. Overall survival also favored TTF, but did not reach statistical significance. In view of the above, TTF should be considered a valid novel treatment modality. [Table: see text]
Phase II study of eribulin (E7389) in patients (pts) with advanced urothelial cancer (UC)—Final report: A California Cancer Consortium-led NCI/CTEP-sponsored trial.
Authors: D. I. Quinn, A. Aparicio, D. D. Tsao-Wei, S. G. Groshen, T. B. Dorff, T. W. Synold, W. M. Stadler, D. R. Gandara, P. Lara, E. M. Newman
Journal: Journal of Clinical Oncology (2010)

4539 Background: There is an unmet need for new agents in locally advanced and metastatic UC, particularly for pts with renal dysfunction. Microtubule directed agents (vincas, taxanes) have activity in UC. A prior first in human phase I study of eribulin, a microtubulin modulator derived from the black Pacific sea sponge toxin showed that eribulin/metabolites are minimally renally excreted (T. Synold, ASCO A2054, 2005). Encouraging activity was evident in UC. Here we report the results of a subsequent ph II study in advanced UC. Methods: The ph II component of this study accrued patients with normal creatinine or calculated CrCl ≥60mL/m, UC: any histological type and no prior cytotoxic therapy for advanced disease (neo/adjuvant allowed). Eribulin 1.4mg/m2 was given IV on d 1 & 8, q3weeks. Endpoints: response rate (RR) >20% was deemed interesting in a 2-stage design requiring ≥2 responses/21 pts to proceed to total 41 pts; PFS and OS. Results: 40 pts entered. Patient characteristics: histology: 35 with transitional, 3 adenocarcinoma, 1 squamous and 1 small cell. Median age: 67 yrs (37-87); Males: 68%; KPS ≥90% in 60%, ≤80% in 40%. Prior neo/adjuvant chemotherapy in 72.5%. Bajorin risk groups: 0: 30%, 1: 57%, 2: 13%. Three were inevaluable (2 off treatment due to toxicity and 1 early death). Overall RR was 38%, 95% CI: (23%, 54%) based on 37 evaluable pts with 1 CR +14 PR, 13/15 responses were in pts with TCC (RR 37% in subgroup). RR in pts with prior neo/adjuvant chemo: 34%. At median follow-up of 19.8 months, median PFS=3.9 months (2.7, 5.3; 36 pts progressed), median OS=9.4 mo (6.7, 11.9; 25 pts dead). PFS was associated with Bajorin risk group (p=0.028 for trend). Toxicities: 20 pts Gr 3/4 neutropenia, no febrile neutropenia, sensory neuropathy: 19 pts (18 Gr 1/2). Other non-hematologic toxicities: hyperglycemia (14, 3 Gr 3), hyponatremia (14, 4 Gr 3), alopecia (37), leg fatigue and aching (6, 1 Gr 3). Conclusions: E7389 has single agent activity in UC, even in pts with prior neo/adjuvant chemotherapy. Further evaluation of this agent in UC is warranted. Accrual is ongoing for pts with CrCl <40mL/m in whom the 1.4mg/m2 dose studied here is also tolerable (U01-CA062505). No significant financial relationships to disclose.
Lymphangioleiomyomatosis – Clinical characteristics and longitudinal follow-up of 36 cases
Authors: Malgorzata Sobiecka, Jan Kus, Stefan Wesolowski, Elzbieta Radzikowska, Maria Korzeniewska-Kosela
Journal: European Respiratory Journal (2011)

Background: Lymphangioleiomyomatosis (LAM) characterized by LAM cells proliferation and cystic lung destruction can occur sporadically (S-LAM) or in association with tuberous sclerosis complex (TSC-LAM).  Aim: To describe the clinical characteristics of subjects with S-LAM and TSC-LAM and to assess changes in pulmonary function test (PFT) during observation.  Methods: Retrospective analysis of 36 women with LAM diagnosed between 1990 – 2010.  Results: There were 25 patients with S-LAM (69%) and 11 cases with TSC-LAM (31%). The mean age of onset of symptoms was 37.4±10.5yr and at diagnosis 40.2±10.1yr. Recurrent pneumothoraces occurred in 22 cases (61%), chylothorax in 4 (11%). Sixteen women (44%) were treated with progesterone. There were 7 deaths, including 4 from respiratory failure (after 6, 7, 11, and 11 yrs). Women with TSC-LAM were younger (32.6±10.2yr vs 43.5±8.3yr; p=0.0018) and more often had renal angiomyolipomas (100% vs 32%; p=0.00003) compared with those with S-LAM. TSC-LAM and S-LAM cases did not differ significantly regarding PFT at presentation. An obstructive pattern was observed in 56% of cases, whereas 35% had normal spirometric results. DLCO was reduced in 83% of patients. The serial biannual measurement of lung function revealed significant reduction in DLCO after 4 yrs (n=13; 49.5±18% pred. vs. 60.8±15.6% pred.; p=0.0038) and it was the earliest significant change in PFTs.  Conclusion: LAM is slowly progressing disease with the first significant deterioration in PFTs after 4 years of follow-up.
Ten essential<i>BJSM</i>podcasts that will improve your practice
Authors: Ania Tarazi
Journal: British Journal of Sports Medicine (2015)

Ten essential BJSM podcasts that will improve your practice Ania TaraziIt's time to extend your sports and exercise medicine (SEM) horizon, enrich your daily practice and enliven your run-commute.Every Tuesday and Friday, #TeamBJSM gives you the chance to hear from your SEM heroes.Now with over 60 000 listens, here are our top 10 podcasts to date: DIAGNOSING AND TREATING ACUTE HAMSTRING INJURIES
A phase II trial of radiotherapy sandwiched between carboplatin and docetaxel for stage III, IV, and recurrent endometrial cancer.
Authors: M. A. Geller, J. Ivy, R. Ghebre, L. S. Downs, P. L. Judson, L. F. Carson, A. L. Jonson, K. Dusenbery, M. Boente, P. Argenta
Journal: Journal of Clinical Oncology (2010)

5029 Background: Management of patients with advanced endometrial cancer remains controversial and the optimal sequence of adjuvant therapy is undetermined. Feasibility and outcomes of administering pelvic radiotherapy (RT) sandwiched between docetaxel (DT) and carboplatin (C) were studied. Methods: Surgically staged IIIA (excluding positive cytology) or greater endometrial cancer, with or without measurable disease and recurrences, not previously treated with chemotherapy or pelvic radiation (RT), were eligible. The protocol included 3 cycles of DT (75 mg/m2) and C (AUC 6) followed by whole pelvic RT (45 Gy) and 3 additional cycles of DT (75 mg/m2) and C (AUC 6). Extended-field RT was given for pelvic or paraaortic lymph node involvement. Kaplan-Meier (KM) survival statistics were calculated for disease free (DFS) and overall survival (OS). Results: Forty-two patients enrolled from August 2004 to June 2009, 40 at initial diagnosis and 2 at recurrence. 6 did not complete therapy and 1 withdrew prior to therapy. Median age = 58 years (range: 21-81). 78% (32/41) = endometrioid histology. Stages = 10 IIIA, 21 IIIC, 8 IV, (recurrent = 1 IC, 1 IIA). 7 had measurable disease after surgery, 36 had lymph nodes removed. Of 227 chemotherapy cycles, 5.3% (12), 3.5% (8), and 2.6% (6), were associated with grade 3/4 neutropenia, GI toxicity, and anemia, respectively. 85% (35/41) completed all 6 prescribed chemotherapy cycles. At a median follow-up of 16.1 months (range: 1.1-50.9), 5 died. KM estimate for OS at 1 year = 94.4% (SE = 3.9%), 2 years = 90.9% (SE = 5.1%), 3 years = 79.5% (SE = 11.5%). There are an insufficient number of deaths to estimate median OS. Eight progressed or died within 3 years of study enrollment. Of recurrences, only one was in the RT field. KM estimate for PFS at 1 year is 88.4% (SE = 5.5%), 2 years= 78.2% (7.4%), 3 years=70.3% (SE = 10.0%). There are an insufficient number of progressions to estimate median PFS. Conclusions: Adjuvant combination modality therapy in a “sandwich” fashion is feasible, well-tolerated and results in excellent long-term PFS and OS. This regimen provides durable long-term disease control in advanced-stage endometrial cancer. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration sanofi-aventis
Co-expression of LPLUNC1 and MUC5B in the bronchiolarized epithelium of usual interstitial pneumonia
Authors: Bianca Araujo, Lynne Bingle, Sarah Howie, William Wallace, Nikhil Hirani, Colin Bingle
Journal: European Respiratory Journal (2011)

Idiopathic Pulmonary Fibrosis (IPF) is an irreversible and progressive lung disease with limited life expectancy after diagnosis. The cause of the condition remains elusive but it has both familial and environmental associations. Histopathological studies of IPF lungs reveal the typical “Usual Interstitial Pneumonia” (UIP) pattern, with epithelial hyperplasia, areas of scarring with fibroblast foci and characteristic morphological abnormalities, including bronchiolization of alveolar ducts, cysts and alveoli. Although it seems likely that bronchiolar abnormalities are caused by changes in epithelial cell differentiation, specific markers of this process remain elusive. By analysis of published array data sets from IPF patients, we identified LPLUNC1 as a potential candidate marker for the disease. This putative innate defence protein is normally expressed in submucosal glands (SMGs) and in a population of MUC5A/C positive goblet cells in the upper airways. Immunohistochemical analysis of lung tissue from patients with UIP revealed strong staining of LPLUNC1 within the bronchiolarized epithelium lining the honeycomb cysts as well as in the mucosubstance filling these regions and dispersed throughout the peripheral lung. The related protein, SPLUNC1 was not co-expressed. MUC5B was localized to the same cells as LPLUNC1, whereas MUC5A/C was found in goblet cells within the airways. The same pattern of staining was not seen in other chronic lung diseases, suggesting a degree of specificity for IPF. Our data support the idea that in UIP, airway epithelial cells develop characteristics of SMGs and suggest that LPLUNC1 may be a useful marker for the disease.
포스터 전시 : 반복된 식도정맥류 출혈 환자에서 거대 재생결절로 오인된 결절성 재생증식 1예
Authors: 왕준광, 손주현, 김진배, 이항락, 김종표, 한동수, 함준수, 이동후, 기춘석, 장세진
Journal: Clinical and Molecular Hepatology (2003)

배경/목적: 결절성 재생증식(nodular regenerative hyperplasia)은 간조직의 재생 결절이 미만적으로 퍼져있는 드문 질환이다. 이는 각 결절 주위에 섬유화가 없는 것으로 간경변에서의 재생결절과 구분된다. 원인은 아직 밝혀지지 않았지만 자가면역질환, 류마티스 질환, 골수증식질환, 만성적 정맥울혈 등과 관계된다는 보고가 있다. 그리고, 드물게 간경변없이 결절성 재생증식에 의하여 문맥압이 상승되어 식도정맥류 같은 합병증을 유발할 수 있는 것으로 되어 있다. 이에 반복적으로 식도정맥류 출혈을 일으켰던 환자에서 처음에 간경변에 의한 거대재생결절(macro-regenerative nodule)로 오인되었던 결절성 재생증식의 1예를 보고하고자 한다. 증례: 32세 남자 환자로 1세 때 뜨거운 물에 얼굴과 우측 수부에 화상을 입은 병력이 있었으나, 기타 다른 기왕력과 간질환의 병력은 없었다. 6년 전 처음 토혈하여 타병원에서 간경변에 의한 식도정맥류 출혈로 치료받았다. 2년 전 식도정맥류 재출혈로 본원 응급실로 처음 내원하여, 내시경적 결찰술을 시행 받았으며, 원인 불명의 문맥고혈압으로 진단받았다. 당시 복부 초음파검사에서 간내에 뚜렷한 결절이 보이지 않았지만, 6개월 후 복부 초음파 검사에서 0.5 cm에서 1.5 cm 크기의 고음영 결절성 병변이 주로 간 좌엽과 우엽의 제8분절에 퍼져있었다. 이때 AFP은 1.7 ng/ml 였지만 복부전산화단층촬영에서 간암을 배제할 수 없었으며, 초음파 유도하 경피적 간조직검사에서 거대재생결절로 판단되었다. 약 1년 후 추적검사한 복부전산화단층촬영에서 간좌엽의 비교적 큰 결절이 좀더 커진 것으로 의심되어 다시 경피적 간조직검사를 시행하였으나, 이전과 같은 거대재생결절로 판단되었다. 문맥 고혈압의 해소와 확실한 진단을 위해 간좌엽 외측분절절제술과 원위부 비신정맥 단락술(distal splenorenal shunt, Warren shunt)을 시행하였다. 수술시 간경변의 소견은 없었으며, 절제된 간조직검사에서 최종적으로 결절성 재생 증식으로 진단되었다. 수술 후 식도정맥류는 더 이상 커지지 않는 상태로 외래 통원치료중이다.
Mitotic, Chromosomal, and Nucleolar Alterations Induced by Thioacetamide in Relation to the Mitotic Cycle After Partial Hepatectomv
Authors: S Mironescu, M Clovîrnache
Journal: JNCI Journal of the National Cancer Institute (1971)

Journal Article Mitotic, Chromosomal, and Nucleolar Alterations Induced by Thioacetamide in Relation to the Mitotic Cycle After Partial Hepatectomv Get access Stefan Mironescu, Stefan Mironescu Department of Morphology, The Institute of Endocrinology, Bucharest, Romania Search for other works by this author on: Oxford Academic PubMed Google Scholar Martha Clovîrnache Martha Clovîrnache Department of Morphology, The Institute of Endocrinology, Bucharest, Romania Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 46, Issue 1, January 1971, Pages 49–61, https://doi.org/10.1093/jnci/46.1.49 Published: 01 January 1971 Article history Received: 07 May 1970 Accepted: 02 October 1970 Published: 01 January 1971
Loss of plasma phospholipid transfer protein (PLTP) activity enhances inflammatory responses to cigarette smoke in the lung
Authors: Anthony Brehm, Patrick Geraghty, Itsaso Garcia-Arcos, Jeanine D'Armiento, Edward Eden, Robert Foronjy
Journal: European Respiratory Journal (2013)

PLTP is a protein that classically functions to shuttle phospholipids amongst lipoprotein particles in the circulation. Though it has been best studied in the plasma, its primary site of expression and activity is within the lung epithelium. This study aimed to determine if cigarette smoke exposure induced inflammatory responses by altering PLTP activity in the lung. PLTP activity was measured in the lung lavage fluid of advanced emphysema subjects (Gold 3 or greater) and age-matched normal controls. Enzymatic activity was significantly reduced in the lung lavage of emphysema subjects. To determine the etiology of this decrease, recombinant PLTP protein was incubated for 24 hours with lung lavage from normals, smokers and emphysema subjects. In contrast to normal lung lavage, lavage fluid from smokers and emphysema subjects degraded PLTP protein via a serine protease sensitive mechanism. To determine the impact of the loss of PLTP activity on lung inflammation, mice in the A/J background were treated via the nares with control siRNA or PLTP siRNA followed by cigarette smoke or LPS exposure. Silencing PLTP expression significantly increased the inflammatory response to both cigarette smoke and LPS exposure in mice. Indeed, siPLTP treated mice had higher ERK activation, γ-inteferon expression and lung lavage cellularity in response to these inflammatory stimuli. Thus, PLTP is an important modulator of lung inflammation and the loss of PLTP activity measured in this disease likely contributes to the damaging inflammatory changes that occur in COPD.
Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer.
Authors: P Canal, C Gay, A Dezeuze, J Y Douillard, R Bugat, R Brunet, A Adenis, P Herait, F Lokiec, A Mathieu-Boue
Journal: Journal of Clinical Oncology (1996)

PURPOSE A pharmacokinetic study was performed during a phase II clinical trial of irinotecan (CPT-11) to confirm the pharmacokinetic profile of this drug and its metabolite and to investigate interpatient and intrapatient pharmacokinetic variations and pharmacokinetic-pharmacodynamic relationships. PATIENTS AND METHODS Twenty-six men and 21 women (mean age, 61 years) with metastatic colorectal cancer, performance status less than 3 (World Health Organization [WHO] scale), and normal renal and hepatic function were administered CPT-11 (350 mg/m2) by 30-minute intravenous (IV) infusion every 21 days. CPT-11 and its metabolites SN-38 and SN-38 glucuronide (SN-38G) were determined by high-performance liquid chromatography (HPLC) using fluorimetric detection. RESULTS The mean CPT-11 clearance and area under the concentration-time curve (AUC) were 15.2 L/h. m2 and 24,769ng. h/mL, respectively. The large difference in SN-38 and SN-38G AUCs (559 v 2,283 ng. h/mL) was suggestive of extensive glucuronidation of SN-38. Interindividual variation in the metabolic ratio ([AUCSN-38 + AUCSN-38Gl/AUCCPT-11) was marked (coefficient of variation [CV] = 51.6%] compared with intrapatient variation in this variable (CV = 32.6%). A significant relationship existed between percentage reduction in neutrophil count and the AUC of CPT-11 (r = .597, P &lt; .001) and SN-38 (r = .559, P &lt; .001). No relationship was identified between any pharmacokinetic parameter and delayed diarrhea or therapeutic outcome. CONCLUSION Interindividual variations in the metabolic ratio suggest interpatient variation in carboxylesterase activity. Furthermore, glucuronidation of SN-38 may also be in part responsible for the large interpatient variability in the total SN-38 AUC. Conversely, low intrapatient variation of this parameter was observed in this study, which indicates a lack of autoinduction of the carboxylesterase system. The relationship between neutropenia and both CPT-11 and SN-38 pharmacokinetic parameters confirms the results of previous studies.
Abstract 6279: The Severity of Nonalcoholic Fatty Liver Disease is Associated with Increased Cardiovascular Risk in a Large Cohort of Non-Obese Asian Subjects
Authors: Ki C Sung, Jeong B Park, Marno C Ryan, Andrew M Wilson, Jin H Kang, Bum S Kim, Byung J Kim
Journal: Circulation (2008)

Bcakgrounds: Non alcoholic fatty liver disease (NAFLD) has been linked independently to cardiovascular disease (CVD) but It is largely unknown if such a relationship between NAFLD and CVD risk relates to severity of liver disease or if it is independent of other potential confounding factors Methods: This study included 30,172 subjects. Based on the presence or absence of steatosis on ultrasound and serum alanine aminotransferase (ALT), subjects were divided into controls, an increased serum ALT group without steatosis and a group with presumed nonalcoholic fatty liver disease (NAFLD), which included a steatosis alone group and a group with presumed non alcoholic steatohepatitis (NASH) with steatosis and an elevated ALT. Results: The odds ratio for 10-year risk by total Framingham risk scores ≥10% was 5.3 times higher in NASH groups. The prevalence of diabetes, hypertension, elevated CRP and metabolic syndrome were all increased up to 15 fold over controls, independent of age, BMI, smoking and exercise habits. Overall CVD risk was significantly greater in NASH than in either steatosis or raised ALT alone. Conclusion: Young, non-obese subjects with NAFLD are at significantly increased CVD risk, especially those with NASH. As well as specific therapy for liver disease, a diagnosis of NAFLD should lead to targeted risk assessment and risk factor modification. Table 1. Prevalence of Cardiovascular Risk Factors and 10- year risk Table 2 Odds Ratios and 95% confidence intervals for Cardiovascular Risk Factors and 10- year risk
Factors predicting tumor size at presentation in breast cancer patients
Authors: A. Rosenberg, L. P. Burke, P. W. Vos, M. Brinson
Journal: Journal of Clinical Oncology (2006)

10609 Background: Early diagnosis of breast cancer improves prognosis. A high percentage of women at our institution present with large breast cancers. Using tumor board records, we investigated the potential covariates associated with tumor size at presentation, including age, race, marital status, and insurance status in order to identify populations at risk for presenting with late stage disease. Methods: Data were obtained from tumor board records of University Health Systems, Greenville, NC, a regional referral center in rural Eastern North Carolina. We analyzed data from patients presenting between 1999 and 2005. Relationships between tumor size at diagnosis and explanatory variables (marital status, age, ethnicity, and insurance status) were explored. Results: 1568 patients with breast cancer were identified of which 32% were African American (AA), 67% were White (W), and 0.6% other. 8.3% of patients had Medicaid; 27%, Medicare; 53.5%, private insurance; 3.4%, HMO; and 6.1% were uninsured. Tumor size was 0.01 to 25 cm and highly skewed so that statistical inferences were conducted on the log of tumor size. Tumors of &gt;5 cm were found in 13.8% of AA women as compared to 6.4% of W women. Overall tumor size in AA women was larger than in W women (p-value = .0000). Marital status was not statistically significant (p-value = .5148). A linear regression model for log tumor size at time of diagnosis using explanatory variables marital status, age, ethnicity, and insurance status showed that only race (p-value = .0000) and age (p-value = .0004) were statistically significant. Older patients presented with somewhat smaller tumors. Most of the variability in log tumor size remained unexplained (r-squared = 4%). Conclusions: AA women were more likely to present with large tumors. While Medicaid patients had larger tumors, insurance status was not statistically significant in the linear regression model due to partial confounding of insurance and race: 20.8% of AA women were on Medicaid compared to 2.6% of W women. No significant financial relationships to disclose.